Pain Management Therapeutics Market is expected to reach US$ 98.69 Bn. at a CAGR of 3.8% during the forecast period 2029. Pain management therapeutics help patients avoid spiraling into a public of chronic pain, or at minimum reduce the severity of pain. Minimally invasive procedures and proper use of medications are implemented to succeed in pain management goals between persons. The growing number of people suffering from chronic disease, rising geriatric population and increasing incidence of chronic pain conditions will continue to encourage the use of pain management drugs are expected to drives in the global pain management therapeutics market. However, side effects caused by certain pain management therapeutics and low adoption in the emerging market is a dynamic restraining growth of the market. Moreover, increasing preference by the general population and ongoing research and development in the pain therapeutics are opportunities in the global market.To know about the Research Methodology :- Request Free Sample Report The report covers an in-depth analysis of driving factors, opportunities, and restraints for gaining the key insight of the market. The report emphasizes on all the key trends that play a significant role in the enlargement of the market from 2023 to 2029. Based on the indication, the cancer pain segment is expected to dominate the xx% market share during the forecast period. Increased in the prevalence of cancer across the globe and an increase in healthcare expenditure universal have improved the evolution of the cancer pain segment. The rising occurrence of cancer and growing awareness about cancer pain therapeutics are the significant causes contributing to the growth cancer pain segment during the forecast period. The online pharmacy segment dominates xx% market share during the forecast period, the increasing trend of online purchasing and growing digitalization are significant growth in the online pharmacies segment. The developed healthcare infrastructure and rising awareness among the user about the benefits of e-commerce are some of the factors dynamic the growth of the global market. The Asia Pacific is expected to account for the largest share of the pain management therapeutics market during the forecast period. The implementation of advanced therapeutics and a large patient pool of chronic pain is expected to propel the development of the pain management therapeutics market in the Asia Pacific over the forecast period. The increasing number of untreated chronic diseases and developing government support to the available diagnosis and treatment facilities will encourage the use of pain management drugs thereby heavy the market during the forecast period. The objective of the report is to present comprehensive analysis of global pain management therapeutics market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global pain management therapeutics market dynamics, structure by analyzing the market segments, and project the global pain management therapeutics market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global pain management therapeutics market make the report investor’s guide.
Global Pain Management Therapeutics Market Scope: Inquire before buying
Global Pain Management Therapeutics Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 76.01 Bn. Forecast Period 2023 to 2029 CAGR: 3.8% Market Size in 2029: US $ 98.69 Bn. Segments Covered: by Drug Class Anticonvulsants Antidepressants Anesthetics Non-steroidal Anti-inflammatory Drugs (NSAIDs) Opioids Antimigraine Agents Others by Indication Neuropathic Pain Fibromyalgia Chronic Back Pain Arthritic Pain Migraine Post-operative Pain Cancer Pain by Distribution Channel Hospitals Pharmacy Retail Pharmacy Online Pharmacy by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Global Pain Management Therapeutics Market Key players
1. Pfizer Inc. 2. Endo International Plc. 3. Depomed Inc. 4. Purdue Pharma L.P. 5. Teva Pharmaceutical Industries Ltd 6. Mallinckrodt Pharmaceuticals 7. AstraZeneca Plc 8. Novartis AG 9. Merck & Co. Inc. 10.Johnson & Johnson Services Inc. 11.GlaxoSmithKline Plc. 12.Abbott Laboratories. 13.Assertio Holdings, Inc. 14.Eli Lilly and Company 15.Viatris Inc. 16.Hisamitsu Pharmaceutical Co.,Inc. 17.CALMAR PAIN RELIEF, LLC 18.Calmare Therapeutics Incorporated 19.Allergan 20.F. Hoffmann-La Roche Ltd Frequently Asked Questions: 1. Which region has the largest share in Global Pain Management Therapeutics Market? Ans: Asia Pacific region holds the highest share in 2022. 2. What is the growth rate of Global Pain Management Therapeutics Market? Ans: The Global Pain Management Therapeutics Market is growing at a CAGR of 3.8% during forecasting period 2023-2029. 3. What is scope of the Global Pain Management Therapeutics market report? Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Pain Management Therapeutics market? Ans: The important key players in the global market are – Pfizer Inc., Endo International Plc., Depomed Inc., Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd, Mallinckrodt Pharmaceuticals, AstraZeneca Plc, Novartis AG, Merck & Co. Inc., Johnson & Johnson Services Inc., GlaxoSmithKline Plc., Abbott Laboratories., Assertio Holdings, Inc., Eli Lilly and Company, Viatris Inc., Hisamitsu Pharmaceutical Co.,Inc., CALMAR PAIN RELIEF, LLC, Calmare Therapeutics Incorporated, Allergan, and F. Hoffmann-La Roche Ltd 5. What is the study period of this market? Ans: The Global Pain Management Therapeutics Market is studied from 2022 to 2029.
Global Pain Management Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Pain Management Therapeutics Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Pain Management Therapeutics Market Analysis and Forecast 6.1. Global Pain Management Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Pain Management Therapeutics Market Analysis and Forecast, by Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Pain Management Therapeutics Market Value Share Analysis, by Drug Class 7.4. Global Pain Management Therapeutics Market Size (US$ Bn) Forecast, by Drug Class 7.5. Global Pain Management Therapeutics Market Analysis, by Drug Class 7.6. Global Pain Management Therapeutics Market Attractiveness Analysis, by Drug Class 8. Global Pain Management Therapeutics Market Analysis and Forecast, by Indication 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Pain Management Therapeutics Market Value Share Analysis, by Indication 8.4. Global Pain Management Therapeutics Market Size (US$ Bn) Forecast, by Indication 8.5. Global Pain Management Therapeutics Market Analysis, by Indication 8.6. Global Pain Management Therapeutics Market Attractiveness Analysis, by Indication 9. Global Pain Management Therapeutics Market Analysis and Forecast, by Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Pain Management Therapeutics Market Value Share Analysis, by Distribution Channel 9.4. Global Pain Management Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel 9.5. Global Pain Management Therapeutics Market Analysis, by Distribution Channel 9.6. Global Pain Management Therapeutics Market Attractiveness Analysis, by Distribution Channel 10. Global Pain Management Therapeutics Market Analysis, by Region 10.1. Global Pain Management Therapeutics Market Value Share Analysis, by Region 10.2. Global Pain Management Therapeutics Market Size (US$ Bn) Forecast, by Region 10.3. Global Pain Management Therapeutics Market Attractiveness Analysis, by Region 11. North America Pain Management Therapeutics Market Analysis 11.1. Key Findings 11.2. North America Pain Management Therapeutics Market Overview 11.3. North America Pain Management Therapeutics Market Value Share Analysis, by Drug Class 11.4. North America Pain Management Therapeutics Market Forecast, by Drug Class 11.4.1. Anticonvulsants 11.4.2. Antidepressants 11.4.3. Anesthetics 11.4.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 11.4.5. Opioids 11.4.5.1. Oxycodones 11.4.5.2. Hydrocodones 11.4.5.3. Tramadol 11.4.5.4. Others 11.4.6. Antimigraine Agents 11.4.7. Others 11.5. North America Pain Management Therapeutics Market Value Share Analysis, by Indication 11.6. North America Pain Management Therapeutics Market Forecast, by Indication 11.6.1. Neuropathic Pain 11.6.2. Fibromyalgia 11.6.3. Chronic Back Pain 11.6.4. Arthritic Pain 11.6.5. Migraine 11.6.6. Post-operative Pain 11.6.7. Cancer Pain 11.7. North America Pain Management Therapeutics Market Value Share Analysis, by Distribution Channel 11.8. North America Pain Management Therapeutics Market Forecast, by Distribution Channel 11.8.1. Hospitals Pharmacy 11.8.2. Retail Pharmacy 11.8.3. Online Pharmacy 11.9. North America Pain Management Therapeutics Market Value Share Analysis, by Country 11.10. North America Pain Management Therapeutics Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Pain Management Therapeutics Market Analysis, by Country 11.12. U.S. Pain Management Therapeutics Market Forecast, by Drug Class 11.12.1. Anticonvulsants 11.12.2. Antidepressants 11.12.3. Anesthetics 11.12.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 11.12.5. Opioids 11.12.5.1. Oxycodones 11.12.5.2. Hydrocodones 11.12.5.3. Tramadol 11.12.5.4. Others 11.12.6. Antimigraine Agents 11.12.7. Others 11.13. U.S. Pain Management Therapeutics Market Forecast, by Indication 11.13.1. Neuropathic Pain 11.13.2. Fibromyalgia 11.13.3. Chronic Back Pain 11.13.4. Arthritic Pain 11.13.5. Migraine 11.13.6. Post-operative Pain 11.13.7. Cancer Pain 11.14. U.S. Pain Management Therapeutics Market Forecast, by Distribution Channel 11.14.1. Hospitals Pharmacy 11.14.2. Retail Pharmacy 11.14.3. Online Pharmacy 11.15. Canada Pain Management Therapeutics Market Forecast, by Drug Class 11.15.1. Anticonvulsants 11.15.2. Antidepressants 11.15.3. Anesthetics 11.15.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 11.15.5. Opioids 11.15.5.1. Oxycodones 11.15.5.2. Hydrocodones 11.15.5.3. Tramadol 11.15.5.4. Others 11.15.6. Antimigraine Agents 11.15.7. Others 11.16. Canada Pain Management Therapeutics Market Forecast, by Indication 11.16.1. Neuropathic Pain 11.16.2. Fibromyalgia 11.16.3. Chronic Back Pain 11.16.4. Arthritic Pain 11.16.5. Migraine 11.16.6. Post-operative Pain 11.16.7. Cancer Pain 11.17. Canada Pain Management Therapeutics Market Forecast, by Distribution Channel 11.17.1. Hospitals Pharmacy 11.17.2. Retail Pharmacy 11.17.3. Online Pharmacy 11.18. North America Pain Management Therapeutics Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Indication 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Pain Management Therapeutics Market Analysis 12.1. Key Findings 12.2. Europe Pain Management Therapeutics Market Overview 12.3. Europe Pain Management Therapeutics Market Value Share Analysis, by Drug Class 12.4. Europe Pain Management Therapeutics Market Forecast, by Drug Class 12.4.1. Anticonvulsants 12.4.2. Antidepressants 12.4.3. Anesthetics 12.4.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 12.4.5. Opioids 12.4.5.1. Oxycodones 12.4.5.2. Hydrocodones 12.4.5.3. Tramadol 12.4.5.4. Others 12.4.6. Antimigraine Agents 12.4.7. Others 12.5. Europe Pain Management Therapeutics Market Value Share Analysis, by Indication 12.6. Europe Pain Management Therapeutics Market Forecast, by Indication 12.6.1. Neuropathic Pain 12.6.2. Fibromyalgia 12.6.3. Chronic Back Pain 12.6.4. Arthritic Pain 12.6.5. Migraine 12.6.6. Post-operative Pain 12.6.7. Cancer Pain 12.7. Europe Pain Management Therapeutics Market Value Share Analysis, by Distribution Channel 12.8. Europe Pain Management Therapeutics Market Forecast, by Distribution Channel 12.8.1. Hospitals Pharmacy 12.8.2. Retail Pharmacy 12.8.3. Online Pharmacy 12.9. Europe Pain Management Therapeutics Market Value Share Analysis, by Country 12.10. Europe Pain Management Therapeutics Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Pain Management Therapeutics Market Analysis, by Country 12.12. Europe Pain Management Therapeutics Market Forecast, by Drug Class 12.12.1. Anticonvulsants 12.12.2. Antidepressants 12.12.3. Anesthetics 12.12.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 12.12.5. Opioids 12.12.5.1. Oxycodones 12.12.5.2. Hydrocodones 12.12.5.3. Tramadol 12.12.5.4. Others 12.12.6. Antimigraine Agents 12.12.7. Others 12.13. Germany Pain Management Therapeutics Market Forecast, by Indication 12.13.1. Neuropathic Pain 12.13.2. Fibromyalgia 12.13.3. Chronic Back Pain 12.13.4. Arthritic Pain 12.13.5. Migraine 12.13.6. Post-operative Pain 12.13.7. Cancer Pain 12.14. Germany Pain Management Therapeutics Market Forecast, by Distribution Channel 12.14.1. Hospitals Pharmacy 12.14.2. Retail Pharmacy 12.14.3. Online Pharmacy 12.15. U.K. Pain Management Therapeutics Market Forecast, by Drug Class 12.15.1. Anticonvulsants 12.15.2. Antidepressants 12.15.3. Anesthetics 12.15.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 12.15.5. Opioids 12.15.5.1. Oxycodones 12.15.5.2. Hydrocodones 12.15.5.3. Tramadol 12.15.5.4. Others 12.15.6. Antimigraine Agents 12.15.7. Others 12.16. U.K. Pain Management Therapeutics Market Forecast, by Indication 12.16.1. Neuropathic Pain 12.16.2. Fibromyalgia 12.16.3. Chronic Back Pain 12.16.4. Arthritic Pain 12.16.5. Migraine 12.16.6. Post-operative Pain 12.16.7. Cancer Pain 12.17. U.K. Pain Management Therapeutics Market Forecast, by Distribution Channel 12.17.1. Hospitals Pharmacy 12.17.2. Retail Pharmacy 12.17.3. Online Pharmacy 12.18. France Pain Management Therapeutics Market Forecast, by Drug Class 12.18.1. Anticonvulsants 12.18.2. Antidepressants 12.18.3. Anesthetics 12.18.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 12.18.5. Opioids 12.18.5.1. Oxycodones 12.18.5.2. Hydrocodones 12.18.5.3. Tramadol 12.18.5.4. Others 12.18.6. Antimigraine Agents 12.18.7. Others 12.19. France Pain Management Therapeutics Market Forecast, by Indication 12.19.1. Neuropathic Pain 12.19.2. Fibromyalgia 12.19.3. Chronic Back Pain 12.19.4. Arthritic Pain 12.19.5. Migraine 12.19.6. Post-operative Pain 12.19.7. Cancer Pain 12.20. France Pain Management Therapeutics Market Forecast, by Distribution Channel 12.20.1. Hospitals Pharmacy 12.20.2. Retail Pharmacy 12.20.3. Online Pharmacy 12.21. Italy Pain Management Therapeutics Market Forecast, by Drug Class 12.21.1. Anticonvulsants 12.21.2. Antidepressants 12.21.3. Anesthetics 12.21.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 12.21.5. Opioids 12.21.5.1. Oxycodones 12.21.5.2. Hydrocodones 12.21.5.3. Tramadol 12.21.5.4. Others 12.21.6. Antimigraine Agents 12.21.7. Others 12.22. Italy Pain Management Therapeutics Market Forecast, by Indication 12.22.1. Neuropathic Pain 12.22.2. Fibromyalgia 12.22.3. Chronic Back Pain 12.22.4. Arthritic Pain 12.22.5. Migraine 12.22.6. Post-operative Pain 12.22.7. Cancer Pain 12.23. Italy Pain Management Therapeutics Market Forecast, by Distribution Channel 12.23.1. Hospitals Pharmacy 12.23.2. Retail Pharmacy 12.23.3. Online Pharmacy 12.24. Spain Pain Management Therapeutics Market Forecast, by Drug Class 12.24.1. Anticonvulsants 12.24.2. Antidepressants 12.24.3. Anesthetics 12.24.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 12.24.5. Opioids 12.24.5.1. Oxycodones 12.24.5.2. Hydrocodones 12.24.5.3. Tramadol 12.24.5.4. Others 12.24.6. Antimigraine Agents 12.24.7. Others 12.25. Spain Pain Management Therapeutics Market Forecast, by Indication 12.25.1. Neuropathic Pain 12.25.2. Fibromyalgia 12.25.3. Chronic Back Pain 12.25.4. Arthritic Pain 12.25.5. Migraine 12.25.6. Post-operative Pain 12.25.7. Cancer Pain 12.26. Spain Pain Management Therapeutics Market Forecast, by Distribution Channel 12.26.1. Hospitals Pharmacy 12.26.2. Retail Pharmacy 12.26.3. Online Pharmacy 12.27. Rest of Europe Pain Management Therapeutics Market Forecast, by Drug Class 12.27.1. Anticonvulsants 12.27.2. Antidepressants 12.27.3. Anesthetics 12.27.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 12.27.5. Opioids 12.27.5.1. Oxycodones 12.27.5.2. Hydrocodones 12.27.5.3. Tramadol 12.27.5.4. Others 12.27.6. Antimigraine Agents 12.27.7. Others 12.28. Rest of Europe Pain Management Therapeutics Market Forecast, by Indication 12.28.1. Neuropathic Pain 12.28.2. Fibromyalgia 12.28.3. Chronic Back Pain 12.28.4. Arthritic Pain 12.28.5. Migraine 12.28.6. Post-operative Pain 12.28.7. Cancer Pain 12.29. Rest Of Europe Pain Management Therapeutics Market Forecast, by Distribution Channel 12.29.1. Hospitals Pharmacy 12.29.2. Retail Pharmacy 12.29.3. Online Pharmacy 12.30. Europe Pain Management Therapeutics Market Attractiveness Analysis 12.30.1. By Drug Class 12.30.2. By Indication 12.30.3. By Distribution Channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Pain Management Therapeutics Market Analysis 13.1. Key Findings 13.2. Asia Pacific Pain Management Therapeutics Market Overview 13.3. Asia Pacific Pain Management Therapeutics Market Value Share Analysis, by Drug Class 13.4. Asia Pacific Pain Management Therapeutics Market Forecast, by Drug Class 13.4.1. Anticonvulsants 13.4.2. Antidepressants 13.4.3. Anesthetics 13.4.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 13.4.5. Opioids 13.4.5.1. Oxycodones 13.4.5.2. Hydrocodones 13.4.5.3. Tramadol 13.4.5.4. Others 13.4.6. Antimigraine Agents 13.4.7. Others 13.5. Asia Pacific Pain Management Therapeutics Market Value Share Analysis, By Indication 13.6. Asia Pacific Pain Management Therapeutics Market Forecast, by Indication 13.6.1. Neuropathic Pain 13.6.2. Fibromyalgia 13.6.3. Chronic Back Pain 13.6.4. Arthritic Pain 13.6.5. Migraine 13.6.6. Post-operative Pain 13.6.7. Cancer Pain 13.7. Asia Pacific Pain Management Therapeutics Market Value Share Analysis, by Distribution Channel 13.8. Asia Pacific Pain Management Therapeutics Market Forecast, by Distribution Channel 13.8.1. Hospitals Pharmacy 13.8.2. Retail Pharmacy 13.8.3. Online Pharmacy 13.9. Asia Pacific Pain Management Therapeutics Market Value Share Analysis, by Country 13.10. Asia Pacific Pain Management Therapeutics Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Pain Management Therapeutics Market Analysis, by Country 13.12. China Pain Management Therapeutics Market Forecast, by Drug Class 13.12.1. Anticonvulsants 13.12.2. Antidepressants 13.12.3. Anesthetics 13.12.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 13.12.5. Opioids 13.12.5.1. Oxycodones 13.12.5.2. Hydrocodones 13.12.5.3. Tramadol 13.12.5.4. Others 13.12.6. Antimigraine Agents 13.12.7. Others 13.13. China Pain Management Therapeutics Market Forecast, by Indication 13.13.1. Neuropathic Pain 13.13.2. Fibromyalgia 13.13.3. Chronic Back Pain 13.13.4. Arthritic Pain 13.13.5. Migraine 13.13.6. Post-operative Pain 13.13.7. Cancer Pain 13.14. China Pain Management Therapeutics Market Forecast, by Distribution Channel 13.14.1. Hospitals Pharmacy 13.14.2. Retail Pharmacy 13.14.3. Online Pharmacy 13.15. India Pain Management Therapeutics Market Forecast, by Drug Class 13.15.1. Anticonvulsants 13.15.2. Antidepressants 13.15.3. Anesthetics 13.15.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 13.15.5. Opioids 13.15.5.1. Oxycodones 13.15.5.2. Hydrocodones 13.15.5.3. Tramadol 13.15.5.4. Others 13.15.6. Antimigraine Agents 13.15.7. Others 13.16. India Pain Management Therapeutics Market Forecast, by Indication 13.16.1. Neuropathic Pain 13.16.2. Fibromyalgia 13.16.3. Chronic Back Pain 13.16.4. Arthritic Pain 13.16.5. Migraine 13.16.6. Post-operative Pain 13.16.7. Cancer Pain 13.17. India Pain Management Therapeutics Market Forecast, by Distribution Channel 13.17.1. Hospitals Pharmacy 13.17.2. Retail Pharmacy 13.17.3. Online Pharmacy 13.18. Japan Pain Management Therapeutics Market Forecast, by Drug Class 13.18.1. Anticonvulsants 13.18.2. Antidepressants 13.18.3. Anesthetics 13.18.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 13.18.5. Opioids 13.18.5.1. Oxycodones 13.18.5.2. Hydrocodones 13.18.5.3. Tramadol 13.18.5.4. Others 13.18.6. Antimigraine Agents 13.18.7. Others 13.19. Japan Pain Management Therapeutics Market Forecast, by Indication 13.19.1. Neuropathic Pain 13.19.2. Fibromyalgia 13.19.3. Chronic Back Pain 13.19.4. Arthritic Pain 13.19.5. Migraine 13.19.6. Post-operative Pain 13.19.7. Cancer Pain 13.20. Japan Pain Management Therapeutics Market Forecast, by Distribution Channel 13.20.1. Hospitals Pharmacy 13.20.2. Retail Pharmacy 13.20.3. Online Pharmacy 13.21. ASEAN Pain Management Therapeutics Market Forecast, by Drug Class 13.21.1. Anticonvulsants 13.21.2. Antidepressants 13.21.3. Anesthetics 13.21.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 13.21.5. Opioids 13.21.5.1. Oxycodones 13.21.5.2. Hydrocodones 13.21.5.3. Tramadol 13.21.5.4. Others 13.21.6. Antimigraine Agents 13.21.7. Others 13.22. ASEAN Pain Management Therapeutics Market Forecast, by Indication 13.22.1. Neuropathic Pain 13.22.2. Fibromyalgia 13.22.3. Chronic Back Pain 13.22.4. Arthritic Pain 13.22.5. Migraine 13.22.6. Post-operative Pain 13.22.7. Cancer Pain 13.23. ASEAN Pain Management Therapeutics Market Forecast, by Distribution Channel 13.23.1. Hospitals Pharmacy 13.23.2. Retail Pharmacy 13.23.3. Online Pharmacy 13.24. Rest of Asia Pacific Pain Management Therapeutics Market Forecast, by Drug Class 13.24.1. Anticonvulsants 13.24.2. Antidepressants 13.24.3. Anesthetics 13.24.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 13.24.5. Opioids 13.24.5.1. Oxycodones 13.24.5.2. Hydrocodones 13.24.5.3. Tramadol 13.24.5.4. Others 13.24.6. Antimigraine Agents 13.24.7. Others 13.25. Rest of Asia Pacific Pain Management Therapeutics Market Forecast, by Indication 13.25.1. Neuropathic Pain 13.25.2. Fibromyalgia 13.25.3. Chronic Back Pain 13.25.4. Arthritic Pain 13.25.5. Migraine 13.25.6. Post-operative Pain 13.25.7. Cancer Pain 13.26. Rest of Asia Pacific Pain Management Therapeutics Market Forecast, by Distribution Channel 13.26.1. Hospitals Pharmacy 13.26.2. Retail Pharmacy 13.26.3. Online Pharmacy 13.27. Asia Pacific Pain Management Therapeutics Market Attractiveness Analysis 13.27.1. By Drug Class 13.27.2. By Indication 13.27.3. By Distribution Channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Pain Management Therapeutics Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Pain Management Therapeutics Market Overview 14.3. Middle East & Africa Pain Management Therapeutics Market Value Share Analysis, by Drug Class 14.4. Middle East & Africa Pain Management Therapeutics Market Forecast, by Drug Class 14.4.1. Anticonvulsants 14.4.2. Antidepressants 14.4.3. Anesthetics 14.4.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 14.4.5. Opioids 14.4.5.1. Oxycodones 14.4.5.2. Hydrocodones 14.4.5.3. Tramadol 14.4.5.4. Others 14.4.6. Antimigraine Agents 14.4.7. Others 14.5. Middle East & Africa Pain Management Therapeutics Market Value Share Analysis, By Indication 14.6. Middle East & Africa Pain Management Therapeutics Market Forecast, by Indication 14.6.1. Neuropathic Pain 14.6.2. Fibromyalgia 14.6.3. Chronic Back Pain 14.6.4. Arthritic Pain 14.6.5. Migraine 14.6.6. Post-operative Pain 14.6.7. Cancer Pain 14.7. Middle East & Africa Pain Management Therapeutics Market Value Share Analysis, by Distribution Channel 14.8. Middle East & Africa Pain Management Therapeutics Market Forecast, by Distribution Channel 14.8.1. Hospitals Pharmacy 14.8.2. Retail Pharmacy 14.8.3. Online Pharmacy 14.9. Middle East & Africa Pain Management Therapeutics Market Value Share Analysis, by Country 14.10. Middle East & Africa Pain Management Therapeutics Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Pain Management Therapeutics Market Analysis, by Country 14.12. GCC Pain Management Therapeutics Market Forecast, by Drug Class 14.12.1. Anticonvulsants 14.12.2. Antidepressants 14.12.3. Anesthetics 14.12.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 14.12.5. Opioids 14.12.5.1. Oxycodones 14.12.5.2. Hydrocodones 14.12.5.3. Tramadol 14.12.5.4. Others 14.12.6. Antimigraine Agents 14.12.7. Others 14.13. GCC Pain Management Therapeutics Market Forecast, by Indication 14.13.1. Neuropathic Pain 14.13.2. Fibromyalgia 14.13.3. Chronic Back Pain 14.13.4. Arthritic Pain 14.13.5. Migraine 14.13.6. Post-operative Pain 14.13.7. Cancer Pain 14.14. GCC Pain Management Therapeutics Market Forecast, by Distribution Channel 14.14.1. Hospitals Pharmacy 14.14.2. Retail Pharmacy 14.14.3. Online Pharmacy 14.15. South Africa Pain Management Therapeutics Market Forecast, by Drug Class 14.15.1. Anticonvulsants 14.15.2. Antidepressants 14.15.3. Anesthetics 14.15.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 14.15.5. Opioids 14.15.5.1. Oxycodones 14.15.5.2. Hydrocodones 14.15.5.3. Tramadol 14.15.5.4. Others 14.15.6. Antimigraine Agents 14.15.7. Others 14.16. South Africa Pain Management Therapeutics Market Forecast, by Indication 14.16.1. Neuropathic Pain 14.16.2. Fibromyalgia 14.16.3. Chronic Back Pain 14.16.4. Arthritic Pain 14.16.5. Migraine 14.16.6. Post-operative Pain 14.16.7. Cancer Pain 14.17. South Africa Pain Management Therapeutics Market Forecast, by Distribution Channel 14.17.1. Hospitals Pharmacy 14.17.2. Retail Pharmacy 14.17.3. Online Pharmacy 14.18. Rest of Middle East & Africa Pain Management Therapeutics Market Forecast, by Drug Class 14.18.1. Anticonvulsants 14.18.2. Antidepressants 14.18.3. Anesthetics 14.18.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 14.18.5. Opioids 14.18.5.1. Oxycodones 14.18.5.2. Hydrocodones 14.18.5.3. Tramadol 14.18.5.4. Others 14.18.6. Antimigraine Agents 14.18.7. Others 14.19. Rest of Middle East & Africa Pain Management Therapeutics Market Forecast, by Indication 14.19.1. Neuropathic Pain 14.19.2. Fibromyalgia 14.19.3. Chronic Back Pain 14.19.4. Arthritic Pain 14.19.5. Migraine 14.19.6. Post-operative Pain 14.19.7. Cancer Pain 14.20. Rest of Middle East & Africa Pain Management Therapeutics Market Forecast, by Distribution Channel 14.20.1. Hospitals Pharmacy 14.20.2. Retail Pharmacy 14.20.3. Online Pharmacy 14.21. Middle East & Africa Pain Management Therapeutics Market Attractiveness Analysis 14.21.1.1. By Drug Class 14.21.1.2. By Indication 14.21.1.3. By Distribution Channel 14.21.1.4. PEST Analysis 14.21.1.5. Key Trends 14.21.1.6. Key Developments 15. South America Pain Management Therapeutics Market Analysis 15.1. Key Findings 15.2. South America Pain Management Therapeutics Market Overview 15.3. South America Pain Management Therapeutics Market Value Share Analysis, by Drug Class 15.4. South America Pain Management Therapeutics Market Forecast, by Drug Class 15.4.1. Anticonvulsants 15.4.2. Antidepressants 15.4.3. Anesthetics 15.4.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 15.4.5. Opioids 15.4.5.1. Oxycodones 15.4.5.2. Hydrocodones 15.4.5.3. Tramadol 15.4.5.4. Others 15.4.6. Antimigraine Agents 15.4.7. Others 15.5. South America Pain Management Therapeutics Market Value Share Analysis, By Indication 15.6. South America Pain Management Therapeutics Market Forecast, by Indication 15.6.1. Neuropathic Pain 15.6.2. Fibromyalgia 15.6.3. Chronic Back Pain 15.6.4. Arthritic Pain 15.6.5. Migraine 15.6.6. Post-operative Pain 15.6.7. Cancer Pain 15.7. South America Pain Management Therapeutics Market Value Share Analysis, by Distribution Channel 15.8. South America Pain Management Therapeutics Market Forecast, by Distribution Channel 15.8.1. Hospitals Pharmacy 15.8.2. Retail Pharmacy 15.8.3. Online Pharmacy 15.9. South America Pain Management Therapeutics Market Value Share Analysis, by Country 15.10. South America Pain Management Therapeutics Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Pain Management Therapeutics Market Analysis, by Country 15.12. Processing Equipment Forecast, by Drug Class 15.12.1. Anticonvulsants 15.12.2. Antidepressants 15.12.3. Anesthetics 15.12.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 15.12.5. Opioids 15.12.5.1. Oxycodones 15.12.5.2. Hydrocodones 15.12.5.3. Tramadol 15.12.5.4. Others 15.12.6. Antimigraine Agents 15.12.7. Others 15.13. Brazil Pain Management Therapeutics Market Forecast, by Indication 15.13.1. Neuropathic Pain 15.13.2. Fibromyalgia 15.13.3. Chronic Back Pain 15.13.4. Arthritic Pain 15.13.5. Migraine 15.13.6. Post-operative Pain 15.13.7. Cancer Pain 15.14. Brazil Pain Management Therapeutics Market Forecast, by Distribution Channel 15.14.1. Hospitals Pharmacy 15.14.2. Retail Pharmacy 15.14.3. Online Pharmacy 15.15. Mexico Pain Management Therapeutics Market Forecast, by Drug Class 15.15.1. Anticonvulsants 15.15.2. Antidepressants 15.15.3. Anesthetics 15.15.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 15.15.5. Opioids 15.15.5.1. Oxycodones 15.15.5.2. Hydrocodones 15.15.5.3. Tramadol 15.15.5.4. Others 15.15.6. Antimigraine Agents 15.15.7. Others 15.16. Mexico Pain Management Therapeutics Market Forecast, by Indication 15.16.1. Neuropathic Pain 15.16.2. Fibromyalgia 15.16.3. Chronic Back Pain 15.16.4. Arthritic Pain 15.16.5. Migraine 15.16.6. Post-operative Pain 15.16.7. Cancer Pain 15.17. Mexico Pain Management Therapeutics Market Forecast, by Distribution Channel 15.17.1. Hospitals Pharmacy 15.17.2. Retail Pharmacy 15.17.3. Online Pharmacy 15.18. Rest of South America Pain Management Therapeutics Market Forecast, by Drug Class 15.18.1. Anticonvulsants 15.18.2. Antidepressants 15.18.3. Anesthetics 15.18.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS) 15.18.5. Opioids 15.18.5.1. Oxycodones 15.18.5.2. Hydrocodones 15.18.5.3. Tramadol 15.18.5.4. Others 15.18.6. Antimigraine Agents 15.18.7. Others 15.19. Rest of South America Pain Management Therapeutics Market Forecast, by Indication 15.19.1. Neuropathic Pain 15.19.2. Fibromyalgia 15.19.3. Chronic Back Pain 15.19.4. Arthritic Pain 15.19.5. Migraine 15.19.6. Post-operative Pain 15.19.7. Cancer Pain 15.20. Rest of South America Pain Management Therapeutics Market Forecast, by Distribution Channel 15.20.1. Hospitals Pharmacy 15.20.2. Retail Pharmacy 15.20.3. Online Pharmacy 15.21. South America Pain Management Therapeutics Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Indication 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Pfizer Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Endo International Plc. 16.3.3. Depomed Inc. 16.3.4. Purdue Pharma L.P. 16.3.5. Teva Pharmaceutical Industries Ltd 16.3.6. Mallinckrodt Pharmaceuticals 16.3.7. AstraZeneca Plc 16.3.8. Novartis AG 16.3.9. Merck & Co. Inc. 16.3.10. Johnson & Johnson Services Inc. 16.3.11. GlaxoSmithKline Plc. 16.3.12. Abbott Laboratories. 16.3.13. Assertio Holdings, Inc. 16.3.14. Eli Lilly and Company 16.3.15. Viatris Inc. 16.3.16. Hisamitsu Pharmaceutical Co.,Inc. 16.3.17. CALMAR PAIN RELIEF, LLC 16.3.18. Calmare Therapeutics Incorporated 16.3.19. Allergan 16.3.20. F. Hoffmann-La Roche Ltd 17. Primary Key Insights